CompletedNot Applicable

Human CNS Tau Kinetics in Tauopathies

United States27 participantsStarted 2017-08-21

Plain-language summary

The goal of this study is to characterize tau kinetics and tau aggregation in the human CNS and to test the hypothesis that tau kinetics are altered (i.e. increased production, decreased clearance, and increased aggregation rate) in tauopathies.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosed with PSP, CBD, or FTD MAPT Exclusion Criteria: * Clotting disorder * Active anticoagulation therapy * Active infection * Meningitis * Recent syncope * Current experimental treatment targeting Aβ or medications thought to influence Aβ production or clearance rates (benzodiazepines, muscarinic agents, or anti-epileptics)

What they're measuring

Tau Fractional Turnover Rate (FTR)

Timeframe: 6 months

Trial details

NCT IDNCT03545126

SponsorWashington University School of Medicine

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-03-04

View on ClinicalTrials.gov More Progressive Supranuclear Palsy (PSP) trials